Translocations of the anaplastic lymphoma kinase (ALK) can be effectively targeted in advanced non-small cell lung cancer by ALK-TKI inhibitors including Crizotinib. However, the development of acquired resistance often limits the duration of these therapies. While several mechanisms of secondary resistance have been already identified, little is known about molecular determinants of primary resistance. In our brief report we investigated the tumor molecular profile of a patient who failed to respond to Crizotinib.
We postulate that the MYC gene may be implicated in the mechanism of primary resistance to ALK inhibitors. We also suggest potential MYC-directed inhibition strategies to overcome primary resistance in advanced ALK-rearranged NSCLC. READ ARTICLE
Translational Oncology DOI:10.1016/j.tranon.2018.09.013
Authors: Karim Rihawi, Roberta Alfieri, Michelangelo Fiorentino, Francesca Fontana, Elisa Capizzi, Andrea Cavazzoni, Mario Terracciano, Silvia La Monica, Alberto Ferrarini, Genny Buson, Pier Giorgio Petronini, Andrea Ardizzoni
